Large VA trial will evaluate effects of semaglutide for AUD
The U.S. Department of Veterans Affairs (VA) is leveraging the enthusiasm around the potential of GLP‐1 receptor agonists in substance use treatment in launching a large clinical trial of semaglutide for veterans with alcohol use disorder (AUD). The department intends to enroll 622 veterans with moderate to severe AUD in the 24‐week placebo‐controlled study.
Authors
- Gary Enos
Publication Details
- Journal
- Alcoholism & Drug Abuse Weekly
- Published
- 2026-08-14
- DOI
- https://doi.org/10.1002/adaw.35017
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00